Navigation Links
Bach Pharma Inc, Developing New Drug, GVT® to Treat Veterans Suffering from Gulf War Illness, and Millions of People Suffering from Neurodegenerative Diseases
Date:8/14/2019

Bach Pharma, Inc., a company based in North Andover, Massachusetts, is continuing its research and development of its drug platform GVT (Monosodium Luminol), created to treat and cure multiple neurodegenerative diseases including Gulf War Illness (GWI), ALS, and Parkinson’s disease among others. Overwhelming data from multiple animal studies have proven that GVT has the potential to help millions of people suffering from neurodegenerative diseases, specifically focusing on Veterans who suffer the effects of Gulf War Illness and related conditions.

In 2001, CEO Mark Henry, working with real estate developer Harold Brooks was able to recognize the immense potential for a drug platform they discovered while searching for drugs to help critically ill people survive. The major accomplishment for Henry was locating and bringing together eight founders were able to attract research institutions all over the world and convince them to work together to help mankind. While never intending to compete with the massive pharmaceutical corporations – the founders realized that this product, GVT, could make a huge difference to millions suffering the effects of Neurodegenerative Diseases. Henry recalls that, “What we experienced in the late 1990s was just short of a miracle. We continue to witness the powerful benefits from these products every day. With new data we discover new medical opportunities.”

Bach Pharma Inc’s primary medical product is GVT which is designed to act as a redox buffer in the patients’ brain cells – minimizing and potentially reversing the effects of Gulf War Illness in Veterans. As of 2019, it is believed that over 250,000 US Veterans suffer from some form of GWI and its associated complications including Parkinson’s disease and ALS.

Having successfully demonstrated effectiveness in several GWI animal models, Bach Pharma is in the midst of a $2.2M capital raise in order to fund the next stage of preclinical testing, specifically a toxicology study for the Veteran’s Administration. Individual Investors, Foundations and Veteran Organizations have already committed over $500,000 to this project. Once the toxicology studies are completed, Bach will qualify for an additional $8 million commitment from the US Department of Defense for additional testing of GVT.

COO Christopher LaFarge believes that GVT will be a safe and effective solution for the millions suffering from Neurodegenerative Diseases, “We have proven that neurodegenerative diseases, GWI, radiation exposure, and other related diseases share a common theme, namely oxidative stress, and that GVT has enormous potential to help millions live reasonably normal lives.”

About Bach Pharma, Inc.: Bach Pharma, Inc. (BACH), a privately held research and development pharmaceutical company, directs the development of therapies for degenerative neurological illnesses. The company’s lead candidate GVT is a novel cytoprotective agent that has powerful anti-oxidant and anti-inflammatory properties, which research has shown can reverse oxidative stress, restore intracellular redox homeostasis and quell inflammation. Due to its strong safety profile along with its ability to cross the retinal and the blood-brain barriers and enter cells of the central nervous system, GVT has the potential to treat serious diseases of the central nervous and immune systems and dramatically reduce the cost of global health care.
BACH is a proud member of the Massachusetts Biotechnology Council and a host company for the Massachusetts Life Science Center Internship Challenge.

Read the full story at https://www.prweb.com/releases/bach_pharma_inc_developing_new_drug_gvt_to_treat_veterans_suffering_from_gulf_war_illness_and_millions_of_people_suffering_from_neurodegenerative_diseases/prweb16499968.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related medicine technology :

1. Pharmagen Announces First Quarter 2013 Results
2. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
3. Aoxing Pharmaceutical Company, Inc. Announces Financial Results For Third Quarter Of 2013 Fiscal Year
4. Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeants Board of Directors
5. ViroPharma er stolt over at bakke op om HAE-dag :-) 2013 og vi hjælper HAE-patienter med at fylde verden med smil
6. RuiYi and Genor BioPharma Collaborate on Development in China of RYI-008, a Novel Therapeutic for Autoimmune Diseases and Cancer
7. RuiYi et Genor BioPharma collaborent au développement du RYI-008 en Chine, un nouveau traitement contre les maladies auto-immunes et le cancer
8. PharmaPoint: Multiple Sclerosis - United Kingdom Drug Forecast and Market Analysis to 2022
9. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
10. Access Pharmaceuticals Reports First Quarter Results
11. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/8/2019)... (PRWEB) , ... October 08, 2019 , ... ... struggle women face in her book, Miracle Baby: A Fertility Doctor’s Fight for ... board-certified OB-GYN and fertility specialist, Noorhasan writes to educate, encourage, advise and support ...
(Date:10/8/2019)... TORONTO (PRWEB) , ... October 08, 2019 , ... ... oral delivery of lipid formulations which includes both soft elastic capsules and liquid ... of these technologies can provide formulators with effective delivery platforms during early-phase development ...
(Date:10/8/2019)... ... October 08, 2019 , ... ChoiceSpine LLC, a privately-held spinal device ... the company’s expertise, deepen its knowledge base, and drive sales growth. , The following ... KC Gilbert promoted to Senior Vice President of Strategic Partnerships; ...
Breaking Medicine Technology:
(Date:10/15/2019)... ... 2019 , ... An October 3 article on CNN Health explains ... points out that both agents are mildly abrasive; so while they may be good ... toothpastes, they are also good at stripping the enamel off of teeth if used ...
(Date:10/15/2019)... ... October 15, 2019 , ... In 2019, Unitek opened its doors to various ... late 2018 . Students who started in July were only entering their second term ... students would have to start over. Then the leadership team at Unitek honored their ...
(Date:10/15/2019)... ... October 15, 2019 , ... Nashville Fertility Center (NFC) is proud to ... to join the practice. In addition to treating general infertility, Dr. Van Heertum offers ... at NFC looks forward to Dr. Van Heertum joining the practice and believes she ...
(Date:10/11/2019)... ... October 11, 2019 , ... Inland Detox, Inc. has just moved ... location has incredible views of the Temecula Valley and it’s the perfect place for ... facility offers both private rooms as well as double occupancy rooms, a 2nd home ...
(Date:10/10/2019)... ... , ... AltMed Florida , one of the fastest growing Medical Marijuana ... opening of its second MÜV™ Medical Cannabis Dispensary on the First Coast – scheduled ... Beach. , Located at Beach Plaza Shopping Center at the corner of Beach Boulevard ...
Breaking Medicine News(10 mins):